⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869160 | 1.00 | — | — | |
| SCHEMBL273776 | 0.80 | — | — | |
| SCHEMBL30683717 | 0.75 | — | — | |
| SCHEMBL29870162 | 0.71 | — | — | |
| SCHEMBL22532537 | 0.71 | — | — | |
| SCHEMBL669218 | 0.71 | — | — | |
| SCHEMBL25503201 | 0.71 | — | — | |
| SCHEMBL17431080 | 0.71 | — | — | |
| SCHEMBL28771442 | 0.71 | — | — | |
| SCHEMBL27223367 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126879-B1 | N-PHENYL SUBSTITUTED INDOLE DERIVATIVES AS MYT1 INHIBITORS FOR THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC (CA) | 2026-01-21 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| CN-119731177-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | disclosed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| CN-117729920-A | Carboxamide pyrrolopyrazines and pyridine compounds useful as MYT1 inhibitors and their use in the treatment of cancer | 修复治疗公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024041440-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| US-20160009721-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20160009721-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20160009721-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007731-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |